Company Overview

MacroGenics, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of antibody-based therapeutics for the treatment of cancer. The company operates primarily within the biotechnology and oncology drug development industries, with a strategic emphasis on engineered monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Its core revenue sources have historically included collaboration agreements, milestone payments, licensing arrangements, and research funding from pharmaceutical partners, while the company continues advancing proprietary clinical-stage oncology programs.

The company’s pipeline is built around proprietary technology platforms including DART (Dual-Affinity Re-Targeting) and Fc optimization technologies designed to enhance immune system targeting and anti-tumor activity. MacroGenics has developed programs targeting HER2, B7-H3, CD123, and other oncology-related antigens. Founded in 2000 and headquartered in Rockville, Maryland, the company evolved from an antibody engineering research enterprise into a clinical-stage oncology developer with multiple strategic partnerships involving global pharmaceutical companies. Its positioning is supported by proprietary antibody engineering capabilities, in-house biologics expertise, and a portfolio of differentiated immuno-oncology candidates.

Business Operations

MacroGenics conducts operations primarily through integrated research and development activities focused on oncology therapeutics. The company’s business is organized around proprietary clinical and preclinical product candidates as well as partnered development programs. Key internal programs have included MARGENZA (margetuximab), an Fc-engineered monoclonal antibody targeting HER2, and investigational molecules such as vobramitamab duocarmazine and lorigerlimab. Revenue generation has depended largely on collaboration agreements, licensing transactions, and development milestones, supplemented by limited product revenue associated with commercialization activities.

The company maintains operations principally in the United States but engages in international clinical development and collaboration arrangements. MacroGenics controls multiple antibody engineering technologies, including the DART platform for bispecific antibodies and Fc-engineering technologies designed to improve immune activation. Major strategic collaborations have included partnerships with Incyte Corporation, Gilead Sciences, and other biotechnology and pharmaceutical companies tied to oncology development programs. Manufacturing activities are supported through internal capabilities and third-party contract manufacturing relationships commonly used in biologics development.

Strategic Position & Investments

MacroGenics’ strategic direction centers on advancing differentiated oncology therapeutics while leveraging partnerships to offset development risk and extend commercialization reach. The company has prioritized antibody-drug conjugates, bispecific antibodies, and immune-modulating therapies as growth areas within oncology. Clinical investment has focused particularly on solid tumor indications with unmet medical need, including HER2-positive cancers and B7-H3-expressing tumors. The company has also pursued data-driven portfolio prioritization intended to concentrate resources on programs with clearer regulatory and commercial potential.

Strategic investments have included continued development of proprietary antibody engineering platforms and advancement of internal clinical assets. MacroGenics has entered licensing and co-development arrangements with larger pharmaceutical firms to monetize platform technologies and support pipeline expansion. Programs involving MARGENZA, developed in collaboration with Incyte Corporation, and historical collaborations associated with DART molecules have represented important components of the company’s broader strategy. The company remains active in emerging immuno-oncology modalities, particularly engineered antibodies designed to improve tumor selectivity and immune system engagement.

Geographic Footprint

MacroGenics is headquartered in Rockville, Maryland, and conducts most corporate, research, and development operations within the United States. The company’s clinical development activities, however, have involved trial sites and regulatory engagement across multiple international regions, including North America, Europe, and parts of the Asia-Pacific region through partner-supported studies and multinational clinical programs.

Its global footprint is primarily driven by collaborative agreements and international clinical infrastructure rather than extensive physical overseas operations. MacroGenics’ therapies and development programs have had commercial and regulatory relevance in major pharmaceutical markets including the United States, the European Union, and selected international oncology markets. Strategic partnerships with multinational pharmaceutical companies have expanded the company’s international operational influence beyond its direct corporate footprint.

Leadership & Governance

MacroGenics was founded by scientists and biotechnology entrepreneurs focused on antibody engineering and cancer immunotherapy innovation. The company’s leadership strategy has emphasized scientific differentiation, disciplined clinical development, and partnership-driven growth. Corporate governance and strategic execution are overseen by an executive team with backgrounds in biotechnology research, oncology development, finance, and pharmaceutical commercialization.

Key executives include:

• Scott Koenig – President and Chief Executive Officer
• Barry D. Quart – Chairman of the Board
• Jeffrey Peters – Vice President and Chief Financial Officer
• Ellen Comegys – Vice President, General Counsel and Corporate Secretary
• Ezio Bonvini – Senior Vice President, Research

Leadership communications in public filings and investor materials have consistently emphasized advancing proprietary oncology platforms, optimizing capital allocation, and pursuing strategic collaborations to support long-term pipeline development.